hATTR-pn

Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
PR Newswire
Wed, 03/8/23 - 09:47 am
Ionis Pharmaceuticals
FDA
eplontersen
hATTR-pn
3 Biotech Stocks With Big Catalysts in June
Motley Fool
Tue, 06/22/21 - 10:55 am
Corbus Pharmaceuticals
lenabasum
clinical trials
Gemini Therapeutics
age-related macular degeneration
Intellia Therapeutics
hATTR-pn